A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease

Abstract

The present invention inter alia relates to a chimeric human CD8 Co-receptor, wherein the CD8 Co-receptor comprises a polypeptide including at least one functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8α Co- receptor, and wherein said polypeptide further comprises at least one CD8β-derived polypeptide region including a functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8β Co-receptor.The present invention also relates to a nucleic acid encoding the chimeric CD8 Co-receptor, a vector comprising the nuclear acid encoding for the chimeric human CD8 Co-receptor, as well as to isolated T-cells being transduced with the nucleic acid or the with the vector, and to isolated T-cells being transduced to express the chimeric CD8 Co-receptor. The invention further relates to a kit for preparing the isolated T-cells of the present invention, as well as to a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having cancer comprising administering the pharmaceutical composition.

Description

A CHIMERIC HUMAN CD8 CO-RECEPTOR, A NUCLEIC ACID ENCODING THE CHIMERIC HUMAN CD8 CO-RECEPTOR, CORRESPONDING VECTORS, ISOLATED T-CELLS TRANSDUCED WITH THE NUCLEIC ACID OR CORRESPONDING VECTORS AND KITS FOR PREPARING THEM, AS WELL AS CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A PATIENT HAVING A DISEASEFIELD OF THE INVENTION

[0001] The present invention relates to a chimeric human CD8 Co-receptor, wherein the Co-receptor comprises a polypeptide including at least one functional polypeptide domain or functional polypeptide motif of a wildtype human CD8a Co- receptor, and wherein said polypeptide further comprises at least one CD8p-derived polypeptide region including a functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Co-receptor. The present invention also relates to a nucleic acid encoding the chimeric CD8 Co-receptor, a vector comprising the nuclear acid encoding for the chimeric human CD8 Co-receptor, as well as to isolated T-cells being transduced, transfected or transformed with the nucleic acid or the with the vector, and to T-cells that express the chimeric CD8 Co-receptor. The invention further relates to a kit for preparing the isolated T-cell of the present invention, as well as to a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having cancer comprising administering the pharmaceutical composition.BACKGROUND OF THE INVENTION

[0002] T-cells are known to be important mediators of adaptive cell-mediated immune responses. Adoptive T-cell therapy (ACT) with T-cell s expressing native or transgenic ap-T-cell receptors (TCRs) is a promising treatment for cancer, as TCRs cover a wide range of potential target antigens [Chandran and Klebanoff, 2019], Native TCR specificities have successfully been exploited for ACT with tumor infiltrating lymphocytes (TILs) for melanoma [Dafni et al., 2019] and other tumors [Chandran and Klebanoff, 2019], or with virus-specific T-cells (VSTs) for viral-associated malignancies [Leung and Heslop, 2019], Transgenic TCR-based ACT allows the genetic redirection of T-cell specificity in a highly specific and reproducible manner, and has produced promising results in melanoma and several solid tumors [Robbins et al., 201 ; Robbins etal., 2015], multiple myeloma (MM) [Rapoport et al., 2015], viral-associated malignancies [Doran et al., 2019] and acute myeloid leukemia (AML) [ Chapuis et al., 2019], Another promising option in ACT is the treatment with chimeric antigen receptor (CAR)-T-cells, which has produced remarkable clinical responses with certain subsets of B cell leukemia or multiple lymphoma [Sterner and Sterner, 2019],

[0003] T-cell antigen recognition and subsequent T-cell activation is known to depend on the interaction between the TCR and peptide-major histocompatibility complex (pMHC) molecules [Davis and Bjdrkman, 1988], In particular, the CD8ap coreceptor plays a major role in CD8 T-cell activation by increasing antigen sensitivity [Holler and Kramz, 2003] and by stabilizing the TCR-pMHC class I (pMHCI) interaction at the cell surface [Luescher et al., 1995], The pMHCI-CD8 interaction is central to these functional roles.

[0004] The CD4 co-receptor stabilizes the interaction between the TCR on CD4 T- cells and the MHC class II molecule on antigen-presenting cells (APCs) [Miceli et al. 1991], It has been reported that during activation of T-cells, the CD4 receptor can fulfill several roles including an adhesion function, a signaling function as well as enhancement of T-cell sensitivity to antigens [Claeys and Vermeire, 2019],

[0005] In the past, ACT largely focused on boosting the quantity and quality of antitumor CD8 cytotoxic T lymphocyte (CTL) responses to generate therapeutic benefits. Only recently, it has been reported that in adoptive therapy experiments, the efficacy of high avidity CD4 T-cells in providing protective tumor immunity was similar to the therapeutic efficacy seen with CD8 T-cells. Specifically, it has been described that a Cotransfer of Class I TCR- and CD8 coding genes generated high avidity CD4 T-cells [Xue et al., 2013],

[0006] High transduction / transfection efficiency is essential in adoptive T-cell therapies to efficiently introduce TCR / CAR genes into T lymphocytes. Despite mediating high rates of responses in some clinical trials, this approach can be limited by dysfunctional T-cells if they are present at high frequencies in the starting material from the patient. The fitness of an individual’s T-cells, driven by age, chronic infection, disease burden and cancer treatment, is therefore likely to be a crucial limiting factor of T-cell therapy [Mehta et al. 2021], Transduction / transfection / transformation efficiency in adoptive T-cell therapies, among other factors, depends on the fitness of the T-cell. The number of engineered T-cell s manufactured is dependent on the proliferative potential, as well as the transfection / transduction potential of the leukapheresis product and can restrict the dose of engineered T-cell s administered. For example, robust T-cellactivation and proliferation has been described to be needed for efficient CAR transduction with retroviral vectors and to be beneficial for efficient CAR transduction with lentiviral vectors [Riviere et al., 2000], Thus, transgenic ap-T-cell receptor, CAR T- cell receptor and / or Co-receptor integration and therefore expression level can be sub- optimal if the leukapheresis product predominantly contains cells with poor transduction / transfection potential due to poor fitness.

[0007] Accordingly, it is an object of the invention to provide for an improvement with respect to the above inconveniences.SUMMARY OF THE INVENTION

[0008] This object is inter alia accomplished by the chimeric CD8 Co-receptors, the isolated nucleic acids, the vectors, the isolated T-cells, the pharmaceutical compositions, the kits, and the methods having the features of the respective independent claims.

[0009] In a first aspect, the invention provides a chimeric human CD8 Co-receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD8a (- derived) polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8a Co- receptor (e.g. Seq ID No. 1), wherein said least one CD8a (-derived) polypeptide region comprises a CD8a (-derived) IG-like domain region; further wherein said polypeptide comprises at least one CD8p (-derived) polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8p Co-receptor (e.g. Seq ID No. 2), wherein said least one CD8p (-derived) polypeptide region comprises a CD8p (-derived) IG-like domain region.

[0010] In a second aspect, the invention provides a chimeric human CD8 Co- receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD8a polypeptide region,, wherein said least one CD8a polypeptide region comprises a CD8a IG-like domain region; further wherein said polypeptide comprises at least one CD8p polypeptide region, wherein said least one CD8p (-derived) polypeptide region comprises a CD8p IG-like domain region.

[0011] For example, overexpression of the chimeric human CD8 Co-receptor according to the present invention in T-cells alongside an engineered transgenic ap-T- cell receptor TCR and / or a chimeric antigen receptor offers several advantages and expands the therapeutic potential of this approach.

[0012] In an embodiment, for example, CD4 cells may be incorporated into TCR-T- cell therapy via overexpression of the chimeric human CD8 Co-receptor according to the present invention, such that it becomes possible to harness their unique properties to augment the antitumor immune response.

[0013] CD4 cells possess the ability to regulate the function of other immune cells, such as CD8 cytotoxic T-cells, dendritic cells, macrophages, and B cells, by providing vital signals through the secretion of cytokines and direct T-cell -cell interactions. This helper function may be crucial for enhancing the persistence and potency of TCR-T-cells within the tumor microenvironment.

[0014] For example, the chimeric human CD8 Co-receptor according to the present invention offers advantages in terms of viral vector packaging efficiency. By utilizing a smaller chimeric CD8 co-receptor polypeptide, the overall size of the therapeutic construct may be reduced, compared with utilization of wildtype human CD8 Co-receptor ap heterodimer, including the complete CD8a polypeptide and the complete CD8p polypeptide. Thus, the chimeric human CD8 Co-receptor according to the present invention enables more efficient packaging of genetic material into the viral vector. For example, it has been reported that the efficiency of packaging a delivery construct, also known as the transfer vector, into lentiviral particles varies greatly depending on the size of the transfer vector. Therefore, advantageously, this increase in packaging efficiency of the chimeric human CD8 Co-receptor according to the present invention leads to higher yields of transduced / transfected T- cells during the manufacturing process, resulting in higher quantities of therapeutically active cells for infusion during adoptive T-cell therapy.

[0015] In addition to the benefits of size reduction, employing the chimeric CD8 co- receptor according to the present invention in TCR-T-cell therapy also offers the advantage of reducing the number of 2A cleavage sites. The 2A peptide sequence is commonly used in gene expression systems to co-express multiple proteins from a single transcript. However, the total number of 2A cleavage sites within the construct that can be theoretically used is limited to four: P2A (Thosea asigna virus 2A), T2A (FMDV 2A), E2A (Equine rhinitis A virus 2A), and F2A (Foot-and-mouth disease virus 2A). Among these, P2A has shown the highest efficiency, followed by T2A and E2A, while F2A has lower cleavage efficiency. Consequently, it is advisable to avoid using F2A, limiting the practical number of 2A sites to three instead of four. Therefore, utilizing the chimeric CD8 co-receptor according to the present invention may enable the efficient incorporation of additional elements into the vector construct design.

[0016] Thus, the chimeric CD8 co-receptor according to the present invention significantly improves manufacturability, efficacy, and the overall success of adoptive T- cell therapy. By increasing viral vector packaging efficiency and reducing the number of 2A cleavage sites, higher quantities of functional TCR-T-cells may be manufactured, thereby improving treatment outcomes for various diseases, particularly cancer.

[0017] In a third aspect, the invention provides an isolated nucleic acid comprising a nuclear acid sequence encoding for the chimeric CD8 Co-receptor according to the present invention.

[0018] In a fourth aspect, the invention provides a vector comprising the nucleic acid according to the present invention.

[0019] In a fifth aspect, the invention provides an isolated T-cell, the T-cell being transduced with the nucleic acid according to the present invention.

[0020] In a sixth aspect, the invention provides an isolated T-cell, the T-cell being transduced with the vector according to the present invention.

[0021] In a seventh aspect, the invention provides an isolated T-cell, the T-cell being transduced to express the chimeric CD8 Co-receptor according to the present invention.

[0022] In an eighth aspect, the invention provides a kit comprising means to prepare the isolated T-cell according to the present invention.

[0023] In a ninth aspect, the invention provides a pharmaceutical composition comprising the isolated T-cell according to the present invention.

[0024] In a tenth aspect, the invention provides a method for preparing a T-cell for immunotherapy, comprising- isolating T-cell s from a human subject,- transducing, transfecting or transforming the T-cells with the nucleic acid according to the present invention or with the vector according to the present invention, and- expanding the transduced, transfected or transformed T-cells.

[0025] In an eleventh aspect, the invention provides a pharmaceutical composition comprising T-cells expressing the chimeric CD8 Co-receptor according to the present invention.

[0026] In a twelfth aspect, the invention provides a method for treating a patient having a disease, comprising administering to the patient the pharmaceutical composition according to the present invention.

[0027] All aspects of the invention provide the above-described advantages and improvements related to the smaller size of the chimeric CD8 Co-receptor in comparison with wildtype CD8 ap Co-receptors.BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the drawings, in which:

[0029] Figs. 1A and 1B show a schematic representation of the construction of the chimeric CD8 Co-receptor according to the present invention. In Fig. 1A both wildtype CD8 a heterodimer and wildtype CD4 Co-receptors are depicted including the functional domains. In particular, the CD8a Co-receptor IG-like domain region, the CD8a stalk region, the CD8a transmembrane domain region, the CD8a LCK binding site, the CD8p Co-receptor IG-like domain region, the CD8p stalk region, the CD8p transmembrane domain, the CD8p palmitoylation motif region, the CD4 stalk region, the CD4 transmembrane domain, and the CD4 cytoplasmic domain including CD4 palmitoylation site and CD4 LCK binding site region are schematically illustrated. In Fig. 1B, the chimeric CD8 Co-receptor according to the present invention including both the CD8a Co-receptor IG-like domain and the CD8p Co-receptor IG-like domain region is illustrated together with optional polypeptide domains / regions / motif sites which may be used for construction of the chimeric CD8 Co-receptor according to the present invention.

[0030] Fig. 2 shows a schematic representation of the chimeric CD8 Co-receptors of the present invention. Functional domains are represented by circles, boxes and rhombuses, respectively. Different color grades are representative of the respective wildtype Co-receptor functional elements are derived from.

[0031] Fig. 3 shows a graphical representation of results from an in-vitro T-cell killing assay of T-cells transduced with chimeric CD8 Co-receptor polypeptides according to the invention.

[0032] Fig. 4 shows a graphical representation of results from a further in-vitro T- cell killing assay of T-cells transduced with chimeric CD8 Co-receptor polypeptides according to the invention.

[0033] Fig. 5 shows a graphical representation of results from a further in-vitro T- cell killing assay of T-cells transduced with chimeric CD8 Co-receptor polypeptides according to the invention.

[0034] Fig. 6 shows a graphical representation of results from a further in-vitro T- cell killing assay of T-cells transduced with chimeric CD8 Co-receptor polypeptides according to the invention.DETAILED DESCRIPTION OF THE INVENTION

[0035] As explained above, in a first aspect the invention is directed to a chimeric human CD8 Co-receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD8a (-derived) polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8a Co-receptor (e.g. Seq ID No. 1), wherein said least one CD8a (-derived) polypeptide region comprises an CD8a (-derived) IG-like domain region; further wherein said polypeptide comprises at least one CD8p (-derived) polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8p Co-receptor (e.g. Seq ID No. 2), wherein said least one CD8p (-derived) polypeptide region comprises an CD8p (-derived) IG-like domain region.

[0036] It is understood that the expression human wildtype CD8a Co-receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P01732 ■ CD8A_HUMAN, as set forth e.g. in SEQ ID No. 1. It is further understood that the expression human wildtype CD8p Co-receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P10966 ■ CD8B_HUMAN, as set forth e.g. in SEQ ID No. 2.

[0037] The term "sequence identity" or "identity" as used in the present invention means the percentage of pair-wise identical residues, following homology alignment of a sequence of a polypeptide and or nucleic acid of the present invention with a sequence in question, with respect to the number of residues in the longer of these two sequences.

[0038] The percentage of sequence homology or sequence identity can, for example, be determined herein using the program BLASTP, version blastp 2.2.5 (November 16, 2002; cf. Altschul, S. F. et al. (1997) Nucl. Acids Res. 25, 3389-3402). The percentage of homology is based on the alignment of the entire polypeptide sequences (matrix: BLOSUM 62; gap costs: 11.1; cutoff value set to 10-3) including therespective sequences. It is calculated as the percentage of numbers of "positives" (homologous amino acids) indicated as result in the BLASTP program output divided by the total number of amino acids selected by the program for the alignment.

[0039] It is noted in this context that it has been surprisingly found here that the chimeric human CD8 Co-receptor polypeptide comprising both an CD8a IG-like domain region together with an CD8p IG-like domain region is able to maintain the function of an CD8a-derived IG-like domain region and an CD8p-derived IG-like domain region being present on individual, separate polypeptides in a wildtype CD8ap co-receptor. The provision of a chimeric CD8 Co-receptor polypeptide comprising both an CD8a-derived IG-like domain region together with an CD8p-derived IG-like domain region therefore, as described above, allows for advantages in terms of viral vector packaging efficiency, by utilizing a smaller chimeric CD8 co-receptor polypeptide.

[0040] According to an embodiment, the at least one CD8a-derived polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8a Co-receptor (e.g. Seq ID No. 1).

[0041] For example, the at least one CD8a-derived polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8a Co-receptor (e.g. Seq ID No. 1).

[0042] According to an embodiment, the at least one CD8p-derived polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Co-receptor (Seq ID No. 2).

[0043] For example, the at least one CD8p-derived polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%,or at least 81%, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Co-receptor (e.g. Seq ID No. 2).

[0044] The at least one CD8a-derived polypeptide region having at least 60% sequence identity with CD8a-derived IG-like domain region of a human wildtype CD8a Co-receptor may have generally a sufficient portion of the human wildtype CD8a IG-like domain region to be able to bind to MHC. For example, said at least one CD8a-derived polypeptide region having at least 60% sequence identity with CD8a-derived IG-like domain region of a human wildtype CD8a Co-receptor may comprise the complete or a considerable part of the human wildtype CD8a IG-like domain region, as set forth e.g. in SEQ ID NO.: 4, but in an embodiment may comprise at least 10, 20, 30, 40, 50, 60, 70, 80, 80, 100, or 110 amino acids of the human wildtype CD8a IG-like domain region. Thus, the expression “Ig-like domain” as used herein may - in principle - refer to a polypeptide region that is homologous to the V and / or C domains in immunoglobuline proteins.

[0045] The at least one CD8p-derived polypeptide region having at least 60% sequence identity with CD8p-derived IG-like domain region of a human wildtype CD8p Co-receptor may have generally a sufficient portion of the human wildtype CD8p IG-like domain region to be able to bind to MHC. For example, said at least one CD8p-derived polypeptide region having at least 60% sequence identity with CD8p-derived IG-like domain region of a human wildtype CD8p Co-receptor may comprise the complete or a considerable part of the human wildtype CD8p IG-like domain region, as set forth e.g. in SEQ ID NO.: 5, but in an embodiment may comprise at least 10, 20, 30, 40, 50, 60, 70, 80, 80, 100, or 110 amino acids of the human wildtype CD8p IG-like domain region. Thus, the expression “Ig-like domain” as used herein may - in principle - refer to a polypeptide region that is homologous to the V and / or C domains in immunoglobuline proteins.

[0046] According to an embodiment, the chimeric human CD8 Co-receptor polypeptide is a single-chain polypeptide.

[0047] According to an embodiment, the chimeric CD8 Co-receptor comprises the CD8a derived IG-like domain region, the CD8p derived IG-like domain region, a stalk region, a transmembrane domain region; and an intracellular / cytoplasmic domain region, wherein the intracellular domain region comprises a palmitoylation motif region and a LCK binding site region.

[0048] The expressions “domain region”, “binding site region”, “motif region” as used herein are understood to relate to e.g. a region of the chimeric CD8 Co-receptor polypeptide which is necessary and / or sufficient for a biological function of the chimeric receptor, or to a region of the chimeric CD8 Co-receptor which is defined e.g. by a localization with respect to a cell, or to a structurally defined unit of the chimeric CD8 Co- receptor polypeptide. Furthermore, the expression “cytoplasmic polypeptide domain” and “cytoplasmic polypeptide motif’ as used herein may be understood as relating to a region of the chimeric CD8 Co-receptor which is defined by its localization in the cytoplasm of a cell, and which is necessary and / or sufficient for a biological function of the chimeric receptor.

[0049] According to an embodiment, the at least one CD8a-derived polypeptide region further comprises at least one polypeptide region selected from the group consisting of a stalk domain region, a transmembrane domain region, and a LCK binding site motif region.

[0050] According to another embodiment, the at least one CD8p-derived polypeptide region further comprises at least one polypeptide region selected from the group consisting of a stalk domain region, a transmembrane domain region, a cytoplasmic region, and a palmitoylation motif region.

[0051] Thus, it is contemplated that the chimeric CD8 Co-receptor polypeptide may comprise, in addition to comprising the CD8a-derived IG-like domain region and the CD8p-derived IG-like domain region, further domain regions / motif regions / binding site regions from one or both of a wildtype human CD8a Co-receptor and / or a wildtype human CD8p Co-receptor in every conceivable combination to establish a functional chimeric CD8 Co-receptor polypeptide.

[0052] For example, it has been described that wildtype human CD8a Co-receptor comprises a stalk domain region, a transmembrane domain region, and a LCK binding site motif region. Furthermore, it has been reported that the human wildtype CD8p- Co-receptor comprises a stalk domain region, a transmembrane domain region, and a palmitoylation motif region (e.g. Wong et al.; 2003).

[0053] For example, the expression “wildtype human CD8a Co-receptor stalk domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 6. For example, the expression “wildtype human CD8a Co-receptor stalk domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 136-182 of UniProtKB database entry No. P01732 ■ CD8A_HUMAN, as set forth e.g. in SEQ ID No. 1. Thus, the expression “stalk region” as used herein may refer to a protein portion that preserves the ability to propagate signal transduction of a functional CD8 Co-receptor analogous to a wildtype human CD8a Co- receptor stalk domain region. For example, the expression “wildtype human CD8a Co- receptor transmembrane domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 7. For example, the expression “wildtype human CD8a Co-receptor transmembrane domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 183-203 of UniProtKB database entry No. P01732 ■ CD8A_HUMAN, as set forth e.g. in SEQ ID No. 1. For example, the expression “wildtype human CD8a Co-receptor LCK binding site motif region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 8. For example, the expression “wildtype human CD8a Co-receptor LCK binding site motif domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence CKCP at amino acid positions 215-218 of UniProtKB database entry No. P01732 ■ CD8A_HUMAN, as set forth e.g. in SEQ ID No. 1. Thus, the expression “LCK binding site” as used herein may refer to a protein portion that preserves the ability to recruite the Src family kinase Lek of a functional CD8 Co-receptor.

[0054] For example, the expression “wildtype human CD8p Co-receptor stalk domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 9. For example, the expression “wildtype human CD8p Co-receptor stalk domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 133-170 of UniProtKB database entry No. P10966 ■ CD8B_HUMAN, as set forth e.g. in SEQ ID No. 2. Thus, the expression “stalk region” as used herein may refer to a protein portion that preserves the ability to propagate signal transduction of a functional CD8 Co-receptor analogous to a wildtype human CD8p Co-receptor stalk domain region. For example, the expression “wildtype human CD8p Coreceptor transmembrane domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 10. For example, the expression “wildtype human CD8p Co-receptor transmembrane domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 171-191 of UniProtKB database entry No. P10966 ■ CD8B_HUMAN, as set forth e.g. in SEQ ID No. 2. For example, expression “the wildtype human CD8p Co-receptor palmitoylation motif region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 11. For example, the expression “wildtype human CD8p Co-receptor palmitoylation motif region” as referred to herein may relate to the two conserved amino acids Cysteine at amino acid positions 194 and 195 with respect to the amino acid sequence of UniProtKB database entry No. P10966 ■ CD8B_HUMAN, as set forth e.g. in SEQ ID No. 2. Thus, the expression “palmitoylation motif region” as used herein may refer to a protein portion that preserves the ability to propagate signal transduction of a functional CD8 Co-receptor analogous to a wildtype human CD8p palmitoylation motif region region.

[0055] According to an embodiment, the chimeric CD8 Co-receptor further comprises at least one CD4 (-derived) polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human CD4 Co-receptor.

[0056] As described herein, the expressions “CD8a-derived polypeptide region”, “CD8p-derived polypeptide region” and “CD4-derived polypeptide region” may be used herein interchangeably with the expressions “CD8a polypeptide region”, “CD8p polypeptide region” and “CD4 polypeptide region”, respectively, to refer to a (functional) portion of a wildtype CD8a, a wildtype CD8p or a wildtype CD4 protein (or variants thereof), respectively. With respect to variants of wildtype CD8a, wildtype CD8p or wildtype CD4 protein portions, such a variant may have at least 60% sequence identity (e.g., at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) to the corresponding portion of the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO: 2 or SEQ ID NO 3, respectively. For example, variants of wildtype CD8a as herein described may comprise an extracellular domain that preserves the ability to bind peptide-MCH class I. Suitable methods (such as e.g. surface plasmon resonance assay) for determining said functional ability are known to the skilled person. For example,variants of wildtype CD8p as herein described may comprise an extracellular domain that preserves the ability to bind peptide-MCH class I. Suitable methods (such as e.g. surface plasmon resonance assay) for determining said functional ability are known to the skilled person. For example, variants of wildtype CD4 protein portions as described herein may comprise a CD4 stalk, a CD4 transmembrane and / or a CD4 cytoplasmic domain that preserves the ability to propagate signal transduction. Suitable methods for determining said functional ability are known to the skilled person (e.g. as described by [Capone M., et al., 2021]).

[0057] It is understood that the expression human wildtype CD4 Co-receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3.

[0058] According to an embodiment, the at least one CD4-derived polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD4 Co-receptor (Seq ID No. 3).

[0059] For example, the at least one CD4 derived polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81%, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD4 Co-receptor (Seq ID No. 3).

[0060] Thus, it is contemplated that the chimeric CD8 Co-receptor polypeptide may comprise, in addition to comprising the CD8a-derived IG-like domain region and the CD8p-derived IG-like domain region, at least one domain region / motif region / binding site region from a wildtype human CD4 Co-receptor. Such at least one CD4-derived domain region / motif region / binding site region may be combined with further CD4- derived domain region / motif region / binding site region and / or further domain regions / motif regions / binding site regions from one or both of a wildtype human CD8a Co- receptor and / or a wildtype human CD8p Co-receptor in every conceivable combination toestablish a functional chimeric CD8 Co-receptor polypeptide. Without being bound to theory, it is herewith contemplated that inclusion of a CD4 Co-receptor derived functional polypeptide domain / motif region / binding site region into the chimeric CD8 Co-receptor may contribute to incorporating CD4 T-cells into TCR-T-cell therapy.

[0061] The wildtype human CD4 Co-receptor polypeptide is known to comprise - among others - a stalk domain region, a transmembrane domain region, and a cytoplasmic region comprising a palmitoylation motif region and a LCK binding site region.

[0062] For example, the expression “wildtype human CD4 Co-receptor stalk domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 12. For example, the expression “wildtype human CD4 Co-receptor stalk domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 375-396 of UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3. For example, the expression “wildtype human CD4 Co-receptor transmembrane domain region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 13. For example, the expression “wildtype human CD4 Co-receptor transmembrane domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 397-418 of UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3. For example, the expression “wildtype human CD8a Co- receptor LCK binding site motif region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 14. For example, the expression “wildtype human CD8a Co-receptor LCK binding site motif domain region” as referred to herein may relate to a polypeptide comprising amino acid sequence 442-449 (KKTCQCPH) of UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3. For example, the expression “wildtype human CD4 Co-receptor palmitoylation motif region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 15. For example, the expression “wildtype human CD4 Co-receptor palmitoylation motif region” as referred to herein may relate to a polypeptide comprising amino acid sequence 419-422 (CVRC) of UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3.

[0063] According to an embodiment, the at least one CD4-derived polypeptide region comprises at least one polypeptide region selected from the group consisting of astalk domain region, a transmembrane domain region, a cytoplasmic domain, a palmitoylation motif region, and a LCK binding site region.

[0064] In certain embodiments, the chimeric CD8 Co-receptor polypeptide may comprise a CD-4 derived polypeptide region comprising a wildtype human CD4 Coreceptor cytoplasmic region including a palmitoylation motif region and a LCK binding site region. For example, the expression “wildtype human CD4 Co-receptor cytoplasmic region” as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 16. For example, the expression “wildtype human CD4 Co- receptor cytoplasmic region” as referred to herein may relate to a polypeptide comprising amino acid sequence 419 - 458 of UniProtKB database entry No. P01730 ■ CD4_HUMAN, as set forth e.g. in SEQ ID No. 3.

[0065] It is contemplated that the chimeric CD8 Co-receptor may comprise a stalk domain region, a transmembrane domain region, a palmitoylation motif region, and a LCK binding site region.

[0066] According to an embodiment, the chimeric CD8 Co-receptor comprises, in an N-terminal to C-terminal order, at least the following plypeptides regions: a CD8a IG- like domain, a CD8p IG-like domain, a stalk region, a transmembrane region, a palmitoylation motif region, a LCK binding site region, and at least one one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif of a tumor necrosis factor receptor superfamily protein and / or of an immunoglobulin superfamily (IgSF) protein, and / or of an ITAM-associated receptor.

[0067] According to certain embodiments, the CD8a-derived IG-like domain region may be located closer to the N-terminal end of the chimeric CD8 Co-receptor polypeptide than the CD8p-derived IG-like domain region. Alternatively, it is herewith also envisaged that the CD8p-derived IG-like domain region may be located closer to the N-terminal end of the chimeric CD8 Co-receptor polypeptide than the CD8a-derived IG-like domain region.

[0068] In some embodiments, the chimeric CD8 Co-receptor polypeptide further comprises at least one linker region.

[0069] For example, the polypeptide may comprise a linker region between the CD8a-derived IG like domain region and said CD8p-derived IG-like domain region.

[0070] Such linker region may comprise 1-100 amino acids, or e.g. 1-80 amino acids, or e.g. 1-50 amino acids, or e.g. 5-100 amino acids.

[0071] According to an embodiment, a linker region of the chimeric CD8 Coreceptor may comprise the amino acid sequence (GGGS)nor (GGGGS)n, wherein n is between 0 and 20, or wherein n is between 0 and 10, or where n is between 0 and 5, or where n is between 3 and 5.

[0072] According to an embodiment, the chimeric CD8 Co-receptor polypeptide may comprise at least one linker region comprising the amino acid sequence (GGGS)n, wherein n is 4.

[0073] According to an embodiment, the chimeric CD8 Co-receptor polypeptide may comprise a linker region between the stalk domain region and the IG-like domain region of the polypeptide.

[0074] According to an embodiment, the chimeric CD8 Co-receptor polypeptide may be able to enhance cytotoxicity of a T-cell.

[0075] In accordance with an embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co- receptor cytoplasmic region. For example, the at least one CD4-derived polypeptide region may also further comprise a CD4-derived Transmembrane domain region, and the stalk domain region may be derived from CD8p. For example, a chimeric CD8 Co- receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 17 (pTK-506), or wherein the polypeptide is having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 18 (pTK-507).

[0076] In accordance with an embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co- receptor cytoplasmic region. For example, the at least one CD4-derived polypeptide region may also further comprise a CD4-derived Transmembrane domain region, andthe stalk domain region may be derived from CD8a. For example, a chimeric CD8 Coreceptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 19 (pTK-508), or wherein the polypeptide is having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:20 (pTK-509).

[0077] According to an embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co-receptor cytoplasmic region. For example, the at least one CD4-derived polypeptide region may also further comprise a CD4-derived Transmembrane domain region. According to this embodiment, also the stalk region may be derived from wildtype human CD4 Co- receptor. Between the CD 4 stalk region and the CD8p-derived IG-like domain region, a linker may be present. According to this embodiment, also between the CD8p-derived IG-like domain region and the CD8a-derived IG-like domain region, a linker may be present. For example, the linker may have an amino acid sequence or (GGGGS)n, wherein n is between 0 and 20, or wherein n is between 0 and 10, or where n is between 0 and 5, or where n is between 3 and 5.

[0078] According to an embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co-receptor cytoplasmic region. In this embodiment, the at least one CD8a-derived polypeptide region may also further comprise a CD8a derived Transmembrane domain region and e.g. a CD8a derived stalk region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, orat least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:21 (pTK-510), or wherein the polypeptide is having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:22 (pTK-511).

[0079] According to an embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co-receptor cytoplasmic region. In this embodiment, the at least one CD8p-derived polypeptide region may also further comprise a CD8p derived Transmembrane domain region and a CD8p-derived stalk domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:23 (pTK-512)

[0080] According to a further embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co- receptor cytoplasmic region. In this embodiment, the at least one CD8a-derived polypeptide region may also further comprise a CD8a derived Transmembrane domain region and the at least one CD8p-derived polypeptide region may comprise a CD8p- derived stalk domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:24 (pTK-519); or in SEQ ID NO: 70(pl_1273); or in SEQ ID NO: 72(pl_1274); or in SEQ ID NO: 74(pl_1274); or in SEQ ID NO: 88(pTK- 0585); or in SEQ ID NO: 90(pTK-0580).

[0081] It is further contemplated that the chimeric CD8 Co-receptor comprising the polypeptide having the amino acid sequence as set forth in SEQ ID NO:24 (pTK-519)may be modified. For example, the cysteine at amino-acid position 54 may be substituted by e.g. alanine. In another embodiment, the serine at position 74 may be substituted by e.g. asparagine. In another embodiment, the cysteine at amino-acid position 164 may be substituted by e.g. a serine. In another embodiment, the cysteine at position 181 may be substituted by e.g. a serine. These modifications are envisaged in each conceivable combination.

[0082] According to another embodiment, the at least one CD4 -derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD4 -derived polypeptide comprises the entire wildtype human CD4 Coreceptor cytoplasmic region. For example, the at least one CD4 -derived polypeptide region may also further comprise a CD4-derived Transmembrane domain region. In this embodiment, the at least one CD8a-derived polypeptide region may also further comprise a CD8a derived stalk region. In this embodiment, the CD8p-derived IG-like domain region may be located closer to the N-terminal end of the chimeric CD8 Coreceptor polypeptide than the CD8a-derived IG-like domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:25 (pTK-513).

[0083] According to another embodiment, the at least one CD4-derived polypeptide region of the chimeric CD8 Co-receptor further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD-4 derived polypeptide comprises the entire wildtype human CD4 Co-receptor cytoplasmic region. For example, the at least one CD8a-derived polypeptide region may also further comprise a CD8a-derived Transmembrane domain region and a CD8a derived stalk region. In this embodiment, the CD8p-derived IG-like domain region may be located closer to the N-terminal end of the chimeric CD8 Co-receptor polypeptide than the CD8a-derived IG-like domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:26 (pTK-514).

[0084] It is further envisaged that the chimeric CD8 Co-receptor may comprise a modified stalk region. For example, the stalk polypeptide region of the chimeric CD8 Coreceptor may comprise a modified CD8a-derived stalk region, a modified CD8p-derived stalk region or a modified CD4-derived stalk region. For example, a modified CD8a- derived stalk region may comprise a polypeptide region which may be elongated, or which may be shortened in length with respect to the length of the wildtype CD8a stalk region. In other embodiments, the CD8 Co-receptor may comprise a modified CD8p- derived stalk region which may be elongated, or which may be shortened in length with respect to the length of the wildtype CD8p stalk region. Also envisaged are embodiments wherein the chimeric CD8 Co-receptor may comprise a modified CD4 derived stalk region which may be elongated, or which may be shortened in length with respect to the length of the wildtype CD4 stalk region.

[0085] According to some embodiments, the chimeric CD8 Co-receptor may comprise a CD8a-derived stalk region which may be shortened in length with respect to the length of the wildtype CD8a stalk region. It has been suggested that the length of the stalk region of Co-receptors may be relevant for establishing the geometry of corresponding ternary TCR-pMHC-Co-receptor complexes (Li et al.; 2013). Without being bound to theory, it is thus contemplated that chimeric CD8 Co-receptors with a truncated CD8a-derived stalk region may mimic functionality of e.g. shorter CD4 stalk regions, thereby contributing to incorporating CD4 T- cells into TCR-T-cell therapy.

[0086] According to an embodiment, the at least one CD4 -derived polypeptide region of the chimeric CD8 Co-receptor thus further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD4 -derived polypeptide comprises the entire wildtype human CD4 Co- receptor cytoplasmic region. Furthermore, the at least one CD4 -derived polypeptide region may also further comprise a CD4 -derived Transmembrane domain region. According to this embodiment, the at least one CDa -derived polypeptide region of the chimeric CD8 Coreceptor further comprises a CD8a-derived stalk region which may be shortened in length with respect to the length of the wildtype CD8a stalk region. In this embodiment, the CD8a -derived IG-like domain region may be located closer to the N- terminal end of the chimeric CD8 Co-receptor polypeptide than the CD8p -derived IG-like domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the aminoacids as set forth in SEQ ID NO:27 (pTK-515) or as set forth in SEQ ID NO:28 (pTK 516).

[0087] According to an embodiment, the at least one CD4 -derived polypeptide region of the chimeric CD8 Co-receptor thus further comprises a CD4 derived palmitoylation motif region, and a CD4-derived LCK binding site region. For example, the at least one CD4 -derived polypeptide comprises the entire wildtype human CD4 Coreceptor cytoplasmic region. In this embodiment, the at least one CD8a-derived polypeptide region may also further comprise a CD8a-derived Transmembrane domain region, and a CD8a-derived stalk region which may be shortened in length with respect to the length of the wildtype CD8a stalk region. According to this embodiment, the CD8a- derived IG-like domain region may be located closer to the N-terminal end of the chimeric CD8 Co-receptor polypeptide than the CD8p-derived IG-like domain region. For example, a chimeric CD8 Co-receptor in accordance with this embodiment may comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO:29 (pTK-517) or as set forth in SEQ ID NQ:30 (pTK 518).

[0088] In a second aspect, the invention provides an isolated nucleic acid comprising a nuclear acid sequence encoding for any one of the human chimeric CD8 Co-receptors according to the present invention.

[0089] The term “polynucleotide” or “nucleic acid” as used herein comprises a sequence of polyribonucleotides and polydeoxribonucleotides, e.g. modified or unmodified RNA or DNA, each in single-stranded and / or double-stranded form linear or circular, or mixtures thereof, including hybrid molecules. The nucleic acids according to this invention thus comprise DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA ivtRNA), combinations thereof or derivatives (such as RNA) thereof.

[0090] A polynucleotide may comprise a conventional phosphodiester bond or a non- conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (RNA)). The polynucleotides of the invention may also contain one or more modified bases, such as, for example, tritylated bases and unusual bases such as inosine. Other modifications, including chemical, enzymatic, or metabolic modifications, are also conceivable, as long as a binding molecule of the invention can be expressed from the polynucleotide. The polynucleotide may be provided in isolated form as defined elsewhere herein. A polynucleotide may include regulatory sequences such astranscription control elements (including promoters, enhancers, operators, repressors, and transcription termination signals), ribosome binding site, introns, or the like.

[0091] For example, the present invention provides a polynucleotide comprising or consisting of a nucleic acid that is at least about 80 %, about 85 %, about 90 %, about 91 %, about 92 %, about 93 %, about 94 %, about 95 %, about 96 %, about 97 %, about 98 %, about 99 %, or 100 % identical to a reference polynucleotide sequence selected from the group consisting of sequences as depicted in SEQ ID NOs: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 71, 73, 75, 89, and 91.

[0092] The polynucleotides described above may or may not comprise additional or altered nucleotide sequences encoding e.g., altered amino acid residues. The polynucleotides may further encode fusion polypeptides, fragments, variants and other derivatives of the chimeric CD8 Co-receptors described herein.

[0093] The nucleic acid sequences of the present invention may be codon- optimized for optimal expression in the desired host T-cell, e.g. a human lymphocyte; or for expression in bacterial, yeast or insect T-cells that are particularly envisaged for the expression of a soluble TCR of the invention. Codon-optimization refers to the exchange in a sequence of interest of codons that are generally rare in highly expressed genes of a given species by codons that are generally frequent in highly expressed genes of such species, such codons encoding the same amino acids as the codons that are being exchanged. Selection of optimum codons thus depends on codon usage of the host genome and the presence of several desirable and undesirable sequence motifs.

[0094] According to a third aspect, the present invention provides a vector comprising the nucleic acid encoding for the chimeric CD8 Co-receptors described herein.

[0095] A “vector” as understood herein relates to a nucleic acid molecule used as a vehicle to transfer (foreign) genetic material into a host T-cell where it can for instance be replicated and / or expressed.

[0096] The vector may be a viral vector or a non-viral vector.

[0097] Viral vectors may be selected from adenoviruses, poxviruses, alphaviruses, arenaviruses, flaviruses, rhabdoviruses, retroviruses, lentiviruses, herpesviruses, paramyxoviruses, picornaviruses, and combinations thereof. Viruses used for transfection of T-cells may include naturally occurring viruses as well as artificial viruses. Viruses may be either an enveloped or non-enveloped virus. Parvoviruses (such as AAVs) are examples of non-enveloped viruses. The viruses may be enveloped viruses. The viruses used for transfection of T-cells may be retroviruses and in particular lentiviruses. Viral envelope proteins that can promote viral infection of eukaryotic cellsmay comprise HIV-1 derived lentiviral vectors (LVs) pseudotyped with envelope glycoproteins (GPs) from the vesicular stomatitis virus (VSV-G), the modified feline endogenous retrovirus (RD114TR), and the modified gibbon ape leukemia virus (GALVTR). These envelope proteins can efficiently promote entry of other viruses, such as parvoviruses, including adeno-associated viruses (AAV), thereby demonstrating their broad efficiency. For example, other viral envelop proteins may be used including Moloney murine leukemia virus (MLV) 4070 env (such as described in Merten et al., J. Virol.79:834-840, 2005; the content of which is incorporated herein by reference), RD114 env, chimeric envelope protein RD114pro or RDpro (which is an RD114-HIV chimera that was constructed by replacing the R peptide cleavage sequence of RD114 with the HIV-1 matrix / capsid (MA / CA) cleavage sequence, such as described in Bell et al. Experimental Biology and Medicine 2010; 235: 1269-1276; the content of which is incorporated herein by reference), baculovirus GP64 env (such as described in Wang et al. J. Virol. 81 :10869-10878, 2007; the content of which is incorporated herein by reference), or GALV env (such as described in Merten et al., J. Virol. 79:834-840, 2005; the content of which is incorporated herein by reference), or derivatives thereof.

[0098] In particular, the term “vector” as used herein encompasses, without limitation, plasmids, viral vectors (including retroviral vectors, lentiviral vectors, adenoviral vectors, vaccinia virus vectors, polyoma virus vectors, and adenovirus- associated vectors (AAV)), phages, phagemids, cosmids and artificial chromosomes (including BACs and YACs). The vector itself is generally a nucleotide sequence, commonly a DNA sequence that comprises an insert (transgene) and a larger sequence that serves as the “backbone” of the vector. Engineered vectors typically comprise an origin for autonomous replication in the host T-cell s (if stable expression of the polynucleotide is desired), selection markers, and restriction enzyme cleavage sites (e.g. a multiple cloning site, MCS). The vector may additionally comprise promoters, genetic markers, reporter genes, targeting sequences, other regulatory elements, and / or protein purification tags. As known to those skilled in the art, large numbers of suitable vectors are known to those of skill in the art and many are commercially available.

[0099] In an embodiment, the vector may further comprise a nucleic acid encoding a chimeric antigen receptor (CAR).

[0100] In an embodiment, the vector may further comprise a nucleic acid encoding a T-cell receptor comprising a TCRa chain and a TCRp chain. For example, the T-cell receptor may be a recombinant T-cell receptor.

[0101] In some embodiments, the transgene may further include one or more multicistronic element(s) and the multicistronic element(s) may be positioned, for example, between any two nucleic acid sequences encoding of TCRa, TCRp, and the chimeric CD8 Coreceptor. In some embodiments, the multicistronic element(s) may include a sequence encoding a ribosome skip element selected from among a T2A, a P2A, a E2A or a F2A or an internal ribosome entry site (IRES).

[0102] As used herein, the term “self-cleaving 2A peptide” refers to relatively short peptides (of the order of 20 amino acids long, depending on the virus of origin) acting co- translationally, by preventing the formation of a normal peptide bond between the glycine and last proline, resulting in the ribosome skipping to the next codon, and the nascent peptide cleaving between the Gly and Pro. After cleavage, the short 2A peptide remains fused to the C-terminus of the 'upstream’ protein, while the proline is added to the N- terminus of the 'downstream’ protein. Self-cleaving 2A peptide may be selected from porcine teschovirus-1 (P2A), equine rhinitis A virus (E2A), Thosea asigna virus (T2A), foot-and-mouth disease virus (F2A), or any combination thereof. By adding the linker sequences (GSG or SGSG (SEQ ID NO: 41)) before the selfcleaving 2A sequence, this may enable efficient synthesis of biologically active proteins, e.g., TCRs and chimeric CD8 Coreceptors as described herein.

[0103] Turning now to a further aspect, there is also provided an isolated T-cell, the T-cell being transduced, transfected or transformed with a nucleic acid encoding for the chimeric human CD8 Co-receptor of the present invention.

[0104] In accordance with another aspect, a T-cell may be transfected, transformed or transduced with a vector comprising a nucleic acid encoding for the chimeric human CD8 Co-receptor of the present invention. According to a further aspect, a T-cell may be transfected, transformed or transduced to express the chimeric CD8 Co-receptor of the present invention.

[0105] The isolated T-cells may be generated using various methods, including those recognized in the literature. For example, a polynucleotide encoding an expression cassette that comprises a tumor recognition, or another type of recognition moiety, and that also encodes for the enhanced chimeric CD8 Co-receptors as herein provided may be stably introduced into the T-cell by a transposon / transposase system or a viral-based gene transfer system, such as a lentiviral or a retroviral system, or another suitable method, such as transfection, electroporation, transduction, lipofection, calcium phosphate (CaPCll), nanoengineered substances, such as Ormosil, mRNA-based therapy, viral delivery methods, including adenoviruses, retroviruses, lentiviruses, adeno-associated viruses, or another suitable method. It is further envisaged that T-cells may be generated in vivo, e.g. by introducing in vivo a nucleic acid as e.g. DNA or mRNA into T-cells, e.g. using nanoparticles such as lipid nanoparticles.

[0106] The T-cells may be transfected or transformed by means known in the art including lipofection (liposome-based transfection), electroporation, calcium phosphate transfection, biolistic particle delivery (e.g., gene guns), microinjection, or combinations thereof. Various methods of transfecting cells are known in the art. See, e.g., Sambrook & Russell (Eds.) Molecular Cloning: A Laboratory Manual (3rd Ed.) Volumes 1-3 (2001) Cold Spring Harbor Laboratory Press; Ramamoorth & Narvekar “Non Viral Vectors in Gene Therapy- An Overview.” JCIinDiagn Res. (2015) 9(1): GE01-GE06.

[0107] According to a further aspect, there is also provided a T-cell expressing the chimeric CD8 Co-receptor as provided in the present invention.

[0108] According to an embodiment, the cell may be a ap T-cell, / _8 T-cell, and / or a natural killer T-cell.

[0109] For example, the ap T-cell may be a CD4 T-cell, or the ap T-cell may be a CD8 T-cell, or the y8 T-cell may comprise e.g. a Vy1 chain or a Vy2 chain, or may be e.g. a Vy9V82+ T-cell.

[0110] It is envisaged that the T-cell may express the chimeric CD 8 Co-receptor as provided by the present invention.

[0111] It is further envisaged that the isolated or engineered T-cell as herein provided may express a heterologous T-cell receptor.

[0112] In certain embodiments, the T-cells may further express an engineered T- cell receptor. Engineered T-cells of the present disclosure may be used to treat a subject in need of treatment for a condition, for example, a cancer described herein. The T-cell may be ap T-cell s or y8 T-cell that express the chimeric CD8 Co-receptor polypeptide as described herein, and optionally an engineered TCR. T-cells described herein may be used to treat a cancer, including solid tumors and hematologic malignancies. For example, “hot” tumors or “cold” tumors may be treated by the T-cells herewith provided.

[0113] According to an embodiment, The T-cells described herein may also be used to treat an infectious disease. The T-cells described herein may be used to treat an infectious disease, an infectious disease may be caused a virus. The T-cell as described herein may be used to treat an immune disease, such as an autoimmune disease. The T-cells may be p T-cell or y8 T-cell that express a chimeric CD8 Co-receptor as described herein, and optionally an engineered TCR.

[0114] According to another aspect, it is herewith provided a kit comprising means to prepare the T-cells described above.

[0115] According to a further aspect, this invention relates to a pharmaceutical composition comprising the T-cell provided by the present invention.

[0116] It is herewith contemplated that the pharmaceutical composition may further comprise an adjuvant, excipient, buffer, diluent, carrier, stabilizer or combination thereof.

[0117] According to a further aspect, there is provided a pharmaceutical composition comprising T-cells which express the chimeric CD8 Co-receptor of the present invention.

[0118] The pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers. Any pharmaceutically acceptable carrier can be used, as long as the carrier does not impact the viability of the T-cell to be administered is suitable for the chosen route of administration of the pharmaceutical composition. The pharmaceutical acceptable carrier may be a physiological saline solution, optionally with components such as human serum albumin that can improve the viability of the T-cell s that express the chimeric CD8 Co-receptor. It is also possible that the chimeric CD8 Coreceptor expressing T-cells are stored, after their manufacture, in frozen form, for example at a temperature of between -20°C and -80 °C. In this case, the pharmaceutical composition may contain cryo-protectants that have been added to protect the cells from being damaged by the freezing process. Examples of croyprotectants that may be used here for the freezing of the pharmaceutical composition containing transduced T-cells include glycerol, DMSO. These cryoprotectant can be used together with crystalloid solutions such as commercially available HypoThermosol® or PlasmaLyte-A solution which are both approved for infusion and are available in pharmaceutical grade. Other possible media that can be used as carrier in the pharmaceutical composition are media of the “CryoStor family”, commercially available animal protein-free defined cryopreservation media from Biolife Solutions such as CyroStor2 (CS2, an optimized freeze media pre-formulated with 2% DMSO), CyroStor5 (CS5, an optimized freeze media pre-formulated with 5% DMSO), or CyroStorlO (CS10, an optimized freeze media pre-formulated with 10% DMSO).

[0119] Turning to a further aspect, a method for preparing a T-cell for immunotherapy is provided, comprising- isolating T-cell s from a human subject,- transducing, transforming or transfecting the T-cell with the nucleic acid as herewith provided, or with the vector as herewith provided, and- expanding the transduced, transfected or transformed T-cell.

[0120] In accordance with a further aspect, a method for treating a patient having a disease, comprising introducing in vivo the nucleic acid or the vector as provided according to the present invention into a T-cell of the patient.

[0121] According to an embodiment, the nucleic acid may be DNA or a mRNA.

[0122] According to an embodiment, the vector may be a non-replicating viral vector.

[0123] In some embodiments, the nucleic acid may be mRNA, and the mRNA may be introduced into the T-cell of the patient using nanoparticles.

[0124] In accordance with a further aspect, there is also provided a method for treating a patient having cancer, comprising administering to the patient the pharmaceutical composition of the present invention.

[0125] For example, a cancer treated by the method may be selected from the group consisting of non-small cell lung cancer, small cell lung cancer, pancreatic cancer, ovarian cancer, melanoma, breast cancer, liver cancer, kidney cancer, esophageal cancer, brain cancer, gastric cancer, Merkel cell carcinoma, leukemia, urinary bladder cancer, uterine cancer, colorectal cancer, gallbladder cancer, bile duct cancer, and prostate cancer.

[0126] For example, the cancer treated may be a solid tumor. In illustrative embodiments of the solid tumor types mentioned above, the lung cancer may be, but is not limited to, non-small cell lung cancer (NSCLC), including squamous cell carcinoma of the lung, adenocarcinoma of the lung, large cell carcinoma of the lung and other histologic types of NSCLC) or small cell lung cancer. In other illustrative examples, the breast cancer may be, but is not limited to, ductal breast cancer, ductal-invasive breast cancer, invasive breast cancer, tubular breast cancer, medullary breast cancer or combinations thereof. In yet other illustrative examples, the gastric cancer may be gastric adenocarcinoma or squamous cell cancer. Turning to sarcoma cancer, the sarcoma cancer may be, but is not limited to, chondrosarcoma cancer, osteosarcoma cancer or combinations thereof. The adenoma cancer may include, but is also not limited to, gastric adenocarcinoma, pancreatic adenocarcinoma or combinations thereof.

[0127] The invention will be further illustrated by the following non-limiting experimental examples.

[0128] Sequences as used herein are depicted in below Table 1.

[0129] Table 1. Sequences as used herein.Experimental Examples

[0130] Example 1. In-vitro T-cell killing analysis of T-cells transduced with chimeric CD8 Co-receptor polypeptides according to the invention

[0131] In order to test the chimeric CD8 Co-receptor constructs described herein for suitability in adoptive T-cell therapy (ACT) with T-cells expressing transgenic a -T- cell receptors, in particular for testing suitability of the chimeric CD8 Co-receptors for incorporating CD4 T- cells into TCR-T-cell therapy, the chimeric CD8 Co-receptor constructs have been used to transduce CD4 T-cells together with an HLA-I restricted TCR raised against MAGE-A1. Purified transduced T-cells were used in an in-vitro T-cell killing assay with NCI-H2030 cells for evaluating cytotoxicity of the transduced T-cells.

[0132] 1.1 Materials and MethodsCloning of chimeric human CD8 Co-receptor constructsChimeric human CD8 Co-receptor constructs have been generated using standard cloning techniques. Table 2 as presented below summarizes the cloned underlying plasmids for chimeric constructs created:

[0133] Table 2

[0134] Table 3 as presented below summarizes the chimeric CD8 Co-receptor constructs that have been generated by the Inventors in a different schematic representation:

[0135] Table 3

[0136] As used in Table 3, the expression “signal peptide” relates to the short peptide region present at the N-terminus of newly synthesized CD8 receptors. The expression “MHC binder 1” relates to the CD8a -derived, or, respectively, CD8p-derived IG-like domain region the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide which is located closer to the N-terminal end of the chimeric CD8 Coreceptor polypeptide. The expression “linker” in Table 3 indicates if - and what kind of - a linker is present between the two IG-like domain regions of the chimeric CD8 Coreceptor polypeptide. The expression “MHC binder 2” relates to the CD8a -derived or, respectively, CD8p-derived IG-like domain region of the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide which is located closer to the C-terminal end of the chimeric CD8 Co-receptor polypeptide. The expression “stalk” according to Table 3 relates to the “stalk” region of the chimeric CD8 Co-receptor polypeptide. The expression “TM” relates to the transmembrane region of the chimeric CD8 Co-receptor polypeptide. Finally, the expression “Intra” according to Table 3 relates to the intracellular domain of the chimeric CD8 Co-receptor polypeptide. In particular, Table 3 thus schematically represents from which wildtype Co-receptor polypeptide (CD4, CD8a or CD8p) the respective polypeptide region of the generated chimeric CD8 Co-receptor polypeptide is derived.

[0137] Table 4 as presented below summarizes the chimeric CD8 Co-receptor constructs that have been generated by the inventors and that have been further analyzed in the T-cell killing assays shown by Fig. 4 and Fig. 5 in schematic representation:

[0138] Table 4

[0139] As used in Table 4, the expression “signal peptide” relates to the short peptide region present at the N-terminus of newly synthesized CD8 receptors. The expression “MHC binder 1” relates to the CD8a -derived, or, respectively, CD8p-derived IG-like domain region the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide which is located closer to the N-terminal end of the chimeric CD8 Coreceptor polypeptide. The expression “linker” in Table 4 indicates if - and what kind of - a linker is present between the two IG-like domain regions of the chimeric CD8 Coreceptor polypeptide. The expression “MHC binder 2” relates to the CD8a -derived or, respectively, CD8p-derived IG-like domain region of the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide which is located closer to the C-terminal end of the chimeric CD8 Co-receptor polypeptide. The expression “stalk” according to Table 4 relates to the “stalk” region of the chimeric CD8 Co-receptor polypeptide. The expression “TM” relates to the transmembrane region of the chimeric CD8 Co-receptor polypeptide. Finally, the expression “Intra” according to Table 4 relates to the intracellular domain of the chimeric CD8 Co-receptor polypeptide. In particular, Table 4 thus relates to chimeric CD8 Co-receptor polypeptides according to the present invention whichmerely differ in the length of the linker sequence between the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide.

[0140] Table 5 as presented below summarizes the chimeric CD8 Co-receptor constructs that have been generated by the inventors and that have been further analyzed in the T-cell killing assay shown by Fig. 6 in schematic representation:

[0141] Table s

[0142] As used in Table 5, the expression “signal peptide” relates to the short peptide region present at the N-terminus of newly synthesized CD8 receptors. The expression “MHC binder 1” relates to the CD8a -derived, or, respectively, CD8p-derived IG-like domain region the two IG-like domain regions of the chimeric CD8 Co-receptor polypeptide which is located closer to the N-terminal end of the chimeric CD8 Co- receptor polypeptide. The expression “linker” in Table 5 indicates if - and what kind of - a linker is present between the two IG-like domain regions of the chimeric CD8 Co- receptor polypeptide. The expression “MHC binder 2” relates to the CD8a -derived or, respectively, CD8p-derived IG-like domain region of the two IG-like domain regions ofthe chimeric CD8 Co-receptor polypeptide which is located closer to the C-terminal end of the chimeric CD8 Co-receptor polypeptide. The expression “stalk” according to Table 5 relates to the “stalk” region of the chimeric CD8 Co-receptor polypeptide. The expression “TM” relates to the transmembrane region of the chimeric CD8 Co-receptor polypeptide. Finally, the expression “Intra” according to Table 5 relates to the intracellular domain of the chimeric CD8 Co-receptor polypeptide. In particular, Table 5 thus relates to chimeric CD8 Co-receptor polypeptides according to the present invention which differ in that either the relative position of the MHC binder is switched (scV19 - which is the same chimeric CD8 Coreceptor as pTK-0519, a nomenclature used elsewhere in this application - comprises the CD8a IG like domain region closer to the N-terminal end of the polypeptide than the CD8p IG like domain region, whereas pl_1278 and pl_1279 comprise comprises the CD8p IG like domain region closer to the N-terminal end of the polypeptide than the CD8p IG like domain region), or in that either the CD8a IG like domain region (in case of construct pl_1276), or the CD8p IG like domain region (in case of construct pl_1277) includes point mutations that are known to decrease binding to the MHC complex. The two constructs pl_1280 and pl_1281 are comparable constructs that completely lack the CD8a IG like domain region.

[0143] Cell Generation

[0144] PBMCs from a healthy donor buffy coat were isolated by density gradient centrifugation with Lymphoprep. Purified polyclonal CD4 T-cells were obtained by negative selection with anti-CD8 microbeads for depleting CD8 population. CD3 T-cells were activated using CD3 / CD28 antibody-coated micro-beads in presence of IL-7 / IL-15. Two days post activation, CD4 T-cells were separately transduced with either HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) alone, or together with wt- CD8ap Coreceptor, or together with different versions of the chimeric CD8 co-receptor (501 to 519), or pl_1272 to pl_1275, pTK-0585, pTK-0580, or pl_1276 to pl_1281. The HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) as used herein has been described e.g. in WO 2014 / 118236, which is herewith incorporated by reference in its entirety. In particular, the HLA-I restricted TCR raised against MAGE-A1 as used herein relates to “TCR1367” as described in WO 2014 / 118236. The CDR sequences of the respective a and p chain of “TCR1367” as used herein are further described -for example - in WO 2023 / 083864, which is herewith incorporated by reference in its entirety. In addition, CD4+ T-cells were transduced with an HLA-I restricted TCR raisedagainst the tumor antigen PRAME (Preferentially Expressed Antigen in Melanoma) together with the chimeric CD8 co-receptor “PTK-519”. This anti-PRAME TCR was raised against the epitope SLLQHLIGL (425-433) that is described in Kessler et al, “Efficient Identification of Novel Hla-A*0201 -Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis”, J. Exp Med (2001) 193 (1): 73-88 by immunizing ABabDR4 mice. ABabDR4 mice carry the complete human TCR loci and are a derivative of ABabDII mice, which were generated as described in Li et al. (2010, Nature Medicine 16, 1029-1034) and first described in Chen et al. (2017, J Exp Med. 214(11): 3417-3433).

[0145] Transduced CD4 T-cell were further expanded, and at Day 9 the transduced fraction was positively selected using CD34 microbeads. Purified transduced T-cells were cultured for further expansion and were harvested and cryopreserved at Day 11. T- cell characterization was based on transgene expression levels using FACS and killing assay.

[0146] Cell Killing assayThe in-vitro T-cellkilling assay was performed according to the method described e.g. by Kalbasi, A., Siurala, M., Su, L.L. et al. “Potentiating adoptive cell therapy using synthetic IL-9 receptors”. Nature 607, 360-365 (2022). In particular, the human TCR T-cell killing assay shown in Fig. 3 was conducted using IncuCyte Live Cell Analysis. NCI-H2030 1x104tumor cells were plated per well in 96-well plates. Untransduced, or transduced human T-cells (transduced with either MAGE_TCR alone, or MAGE_TCR together with wt-CD8ap Co-receptor, or transduced with MAGE_TCR together with a respective one of the chimeric CD8 Co-receptors of the present invention) were added in triplicates at 3 to 1 E:T ratio. The analogous experiment will be carried out with the T cells transduced with the genes encoding the PRAME binding TCR and the chimeric CD8 Co-receptor “PTK- 519” of the present invention. The human TCR T-cell killing assay shown in Fig. 4 was conducted using IncuCyte Live Cell Analysis. NCI-H2030 1x104tumour cells were plated per well in 96-well plates. Untransduced, mock-transduced, or transduced human T-cells (transduced with MAGE_TCR together with a respective one of the chimeric CD8 Coreceptors scV19 (=pTK-0519), scV19_”No Linker”(=pl_1272 in Table 4), scV19_(GGGS)x1 (=pl_1273 in Table 4), scV19_(GGGS)x2 (=pl_1274 in Table 4), or scV19_(GGGS)x3 (=pl_1275 in Table 4)) were added in triplicates at 1 to 1 E:T ratio. The human TCR T-cell killing assay shown in Fig. 5 was conducted using IncuCyte Live Cell Analysis. NCI-H2030 1x104tumour cells were plated per well in 96-well plates.Untransduced, mock-transduced, or transduced human T-cells (transduced with MAGE_TCR together with a respective one of the chimeric CD8 Co-receptors 519 (=pTK-519), 580 (=pTK-0580) or 585 (=pTK-0585)) were added in triplicates at 5 to 1 E:T ratio. The human TOR T-cell killing assay shown in Fig. 6 was conducted using IncuCyte Live Cell Analysis. NCI-H2030 1x104tumour cells were plated per well in 96-well plates. Untransduced, mock-transduced, or transduced human T-cells (transduced with MAGE_TCR together with a respective one of the chimeric CD8 Co-receptors scV19 (=pTK-519), pl_1276, pl_1277, pl_1278, pl_1279, pl_1280 or pl_1281) were added in triplicates at 1 to 1 E:T ratio.

[0147] 1.2 T-cell killing assay analysis

[0148] The Relative cell growth has been observed over time for each transduced T-cell fraction. The results are shown in Fig 3, Fig 4, Fig 5 and Fig 6, respectively. “Mock” relates to mock-transduced T-cell fraction, “MAGE_TCR” relates to CD4 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE- A1_TCR); “wt-CD8” relates to CD4 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with wt-CD8ap Coreceptor; “501” - “519” relates to the CD4 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with the respective chimeric CD8 Coreceptor (“pTK 501” - pTK519”, respectively) as herewith provided. “pl_1276” - “pl_1281” relates to the CD4 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with the respective chimeric CD8 Coreceptor (“pl_1276” - “pl_1281”, respectively) as herewith provided. “580” and “585” relates to the CD4 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with the respective chimeric CD8 Co-receptor (“pTK-0580” and “pTK-0585”, respectively) as herewith provided. “scV19_No linker”, “scV19_(GGGS)x1”, “scV19_(GGGS)x2” and “scV19_(GGGS)x3 ’’relate to the CD4 T- cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE- A1_TCR) together with the respective chimeric CD8 Co-receptor (“pl_1272” - “pl_1274”, respectively) as herewith provided. Again, the analogous experiment will be carried out with the T cells transduced with the genes encoding the PRAME binding TCR and the chimeric CD8 Co-receptor “pTK 519” of the present invention.

[0149] 1.3. Results

[0150] As visible from Fig. 3, Co-transduction of CD4 cells with an engineered HLA-I restricted TCR raised against MAGE-A1 together with a chimeric CD8 Co-receptor as herewith provided results in an increased killing activity of the engineered T-cells compared with mock transduced T-cells and / or T-cells merely transduced with the HLA-I restricted TCR raised against MAGE-A1. The most effective chimeric CD8 Co-receptor is “pTK 519”. As visible from Fig. 4, an increase in length of the linker from 0 over 4 and 8 to 12 or 16 amino acids, respectively, between the CD8a and the CD8p IG-like domain region of the chimeric CD8 Co-receptor polypeptide leads to an enhanced killing activity in the assay. As visible from Fig. 5, a further increase in length of the linker from 16 to 20 or 25 amino acids, respectively, between the CD8a and the CD8p IG-like domain region of the chimeric CD8 Co-receptor does not lead to a further enhanced killing activity. As visible from Fig. 6, chimeric CD8 Co-receptor polypeptides with descreased MHC binding, chimeric CD8 Co-receptor polypeptides comprising only one single CD8p MHC- binder, and chimeric CD8 Co-receptor polypeptides pl_1278 and pl_1279 fail to demonstrate cytotoxic activity.

[0151] Summary and conclusions

[0152] The results described above demonstrate - in principle - suitability of the chimeric CD8 Co-receptor polypeptides as herewith presented in adoptive cell therapy (ACT). Specifically, it is contemplated that the chimeric CD8 Co-receptor polypeptides of the present invention may be functional in generating high avidity CD4 T-cells following Co-transfer with e.g. engineered antigen specific TCRs. Thus, it is contemplated that the reduced size of the functional chimeric CD8 Co-receptor polypeptides as described herein may advantageously address the problem of low transduction efficiency in ACT’S with T-cells of patients having poor overall fitness. Furthermore, as described above, the reduced size of the chimeric CD8 Co-receptor polypeptides as described herein may allow e.g. Co-transduction of one or further additional polypeptides, since the smaller size of the vector (and - as described above - possible omission of at least self-cleaving 2A peptide in comparison two transduction of wildtype CD8ap polypeptides) may allow for Co-transduction of the at least one additional polypeptide without negatively affecting transduction efficiency (e.g. due to very large vector sizes).

[0153] It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0154] All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[0155] The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. Further embodiments of the invention will become apparent from the following claims.

Claims

Claims:What is claimed is:1.A chimeric human CD8 Co-receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD8a polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8a Co-receptor as set forth in Seq ID No. 1 , wherein said least one CD8a polypeptide region comprises an CD8a IG-like domain region; further wherein said polypeptide comprises at least one CD8p polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8p Co-receptor as set forth in Seq ID No. 2, wherein said least one CD8p polypeptide region comprises an CD8p IG-like domain region.

2. A chimeric human CD8 Co-receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD8a polypeptide region comprising an CD8a IG-like domain region; further wherein said polypeptide comprises at least one CD8p polypeptide region comprising an CD8p IG-like domain region.

3. The chimeric CD8 Co-receptor of claim 1 or 2, wherein the Co-receptor further comprises at least one CD4 polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a wildtype human CD4 Co-receptor as set forth in Seq ID No. 3.

4. The chimeric CD8 Co-receptor of any one of claims 1 to 3, wherein said polypeptide is a single-chain polypeptide.

5. The chimeric CD8 Co-receptor according to any one of claims 1-4, wherein the Co- receptor comprises said CD8a IG-like domain region, said CD8p IG-like domain region, a stalk region, a transmembrane domain region; and an intracellulardomain region, wherein the intracellular domain region comprises a palmitoylation motif region and a LCK binding site region.

6. The chimeric CD8 Co-receptor of any one of the foregoing claims, wherein the at least one CD8a polypeptide region further comprises at least one polypeptide region selected from the group consisting of a stalk domain region, a transmembrane domain region, and a LCK binding site motif region.

7. The chimeric CD8 Co-receptor of any one of the foregoing claims, wherein the at least one CD8p polypeptide region further comprises at least one polypeptide region selected from the group consisting of a stalk domain region, a transmembrane domain region, and a palmitoylation motif region.

8. The chimeric CD8 Co-receptor according to any one of claims 3-7, wherein the at least one CD4 polypeptide region comprises at least one polypeptide region selected from the group consisting of a stalk domain region, a transmembrane domain region, a palmitoylation motif region, and a LCK binding site region.

9. The chimeric CD8 Co-receptor according to any one of the foregoing claims, wherein said polypeptide comprises a stalk domain region, a transmembrane domain region, a palmitoylation motif region, and a LCK binding site region.

10. The chimeric CD8 Co-receptor according to any one of the foregoing claims, wherein the CD8a IG-like domain region is located closer to the N-terminal end of said chimeric CD8 Co-receptor polypeptide than the CD8p IG-like domain region.

11. The chimeric CD8 Co-receptor according to any one of claims 1-9, wherein the CD8p-derived IG-like domain region is located closer to the N-terminal end of said chimeric CD8 Co-receptor polypeptide than the CD8a IG-like domain region.

12. The chimeric CD8 Co-receptor according to any one of the foregoing claims, wherein the polypeptide further comprises at least one linker region.

13. The chimeric CD8 Co-receptor according to claim 12, wherein the polypeptide comprises a linker region between said CD8a IG like domain region and said CD8p IG-like domain region.

14. The chimeric CD8 Co-receptor according to claim 12 or 13, wherein the linker region comprises 0-100 amino acids, or wherein the linker region comprises 0-80 amino acids, or wherein the linker region comprises 0-50 amino acids, or wherein the linker region comprises 5-100 amino acids.

15. The chimeric CD8 Co-receptor according to any one of claim 13 - 14, wherein the linker region comprises the amino acid sequence (GGGS)nor (GGGGS)n, wherein n is between 0 and 20, or wherein n is between 2 and 6, or wherein n is between 3 and 5.

16. The chimeric CD8 Co-receptor according to claim 15, wherein the linker region comprises the amino acid sequence (GGGS)n, wherein n is 4.

17. The chimeric CD8 Co-receptor of any one of claims 13-16, further comprising a linker region between the stalk domain region and the IG-like domain region of the polypeptide.

18. The chimeric CD8 Co-receptor of any one of the foregoing claims, wherein the at least one CD8a-derived polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8a Co-receptor, e.g. as set forth in Seq ID No. 1.

19. The chimeric CD8 Co-receptor of any one of the foregoing claims, wherein the at least one CD8p polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Co-receptor, e.g. as set forth in Seq ID No. 2.

20. The chimeric CD8 Co-receptor of any one of claims 3-19, wherein the at least one CD4 polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD4 Co-receptor, e.g. as set forth in Seq ID No. 3.

21. The chimeric CD8 Co-receptor of any one of the foregoing claims, wherein the chimeric Co-receptor is able to enhance cytotoxicity of a T-cell.

22. The chimeric CD8 Co-receptor of any one of claim 8-21 , wherein the at least one CD4-derived polypeptide region further comprises a CD4 palmitoylation motif region, and / or a CD4 LCK binding site region.

23. The chimeric CD 8 Co-receptor according to claim 22; wherein the at least one CD4 polypeptide region further comprises a CD4 Transmembrane domain region.

24. The chimeric CD8 Co-receptor of claim 23, wherein the at least one CD8p polypeptide region further comprises a CD8p stalk domain region.

25. The chimeric CD8 Co-receptor according to claim 24, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 17 (pTK-506), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 18 (pTK-507).

26. The chimeric CD8 Co-receptor of claim 23, wherein the at least one CD8a- derived polypeptide region further comprises a CD8a-derived stalk domain region.

27. The chimeric CD8 Co-receptor according to claim 26, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 19 (pTK-508), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100%, identity to the amino acids as set forth in SEQ ID NO:20 (pTK-509).

28. The chimeric CD8 Co-receptor of claim 23, wherein the at least one CD4 polypeptide region further comprises a CD4 stalk domain region.

29. The chimeric CD8 Co-receptor according to claim 28, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 31 (pTK-527), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 32 (pTK-528); or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 33 (pTK-529).

30. The chimeric CD 8 Co-receptor according to claim 22; wherein the at least one CD8a polypeptide region further comprises a CD8a Transmembrane domain region.

31. The chimeric CD8 Co-receptor of claim 30, wherein the at least one CD8a polypeptide region further comprises a CD8a stalk domain region.

32. The chimeric CD8 Co-receptor according to claim 31, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 21 (pTK-510), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 22 (pTK-511).

33. The chimeric CD8 Co-receptor of claim 30, wherein the at least one CD8p polypeptide region further comprises a CD8p stalk domain region.

34. The chimeric CD8 Co-receptor of claim 32, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100%, identity to the amino acids as set forth in SEQ ID NO: 24 (pTK-519), or in SEQ ID NO: 34 (pTK-577); or in SEQ ID NO: 35 (pTK-578); or in SEQ ID NO: 36 (pTK-579); or in SEQ ID NO:37 (pTK-580); or in SEQ ID NO: 38 (pTK-585); or in SEQ ID NO: 39 (pTK-586); or in SEQ ID NO: 40 (pTK-587); or in SEQ ID NO: 41(pTK-588); or in SEQ ID NO: 70(pl_1273); or in SEQ ID NO: 72(pl_1274); or in SEQ ID NO: 74(pl_1274); or in SEQ ID NO: 88(pTK-0585); or in SEQ ID NO: 90(pTK-0580).

35. The chimeric CD 8 Co-receptor according to claim 22; wherein the at least one CD8p polypeptide region further comprises a CD8p Transmembrane domain region.

36. The chimeric CD8 Co-receptor of claim 25, wherein the at least one CD8p polypeptide region further comprises a CD8p stalk domain region.

37. The chimeric CD8 Co-receptor according to claim 36, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 23 (pTK-512).

38. The chimeric CD8 Co-receptor according to claim 22, further wherein the at least one CD4 polypeptide region comprises the CD4 palmitoylation motif region, and the CD4 LCK binding site region, optionally an entire CD4 cytoplasmic region; and further wherein said at least one CD4 polypeptide region comprises a CD4 transmembrane region; and further wherein said at least one CD8a polypeptide region comprises a CD8a stalk region; wherein said CD8p IG-like domain region is located closer to the N-terminal end of the chimeric CD8 Co-receptor polypeptide than said CD8a IG-like domain region.

39. The chimeric Co-receptor according to claim 38, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 25 (pTK-513).

40. The chimeric CD8 Co-receptor according to claim 22, further wherein the at least one CD4polypeptide region comprises the CD4palmitoylation motif region, and the CD4 LCK binding site region, optionally an entire CD4 cytoplasmic region; and further wherein said at least one CD8apolypeptide region comprises a CD8atransmembrane region; and further wherein said at least one CD8a polypeptide region comprises a CD8a stalk region; wherein said CD8p IG-likedomain region is located closer to the N-terminal end of the chimeric CD8 Coreceptor polypeptide than said CD8a IG-like domain region.

41. The chimeric Co-receptor according to claim 40, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 26 (pTK-514).

42. The chimeric CD8 Co-receptor according to claim 9, wherein said stalk domain region is a modified stalk domain region.

43. The chimeric CD8 Co-receptor according to claim 42, wherein said modified stalk domain region comprises a modified CD8a stalk region.

44. The chimeric CD8 Co-receptor according to claim 43, wherein said modified CD8a stalk region is shortened in length with respect to the wildtype CD8a stalk region.

45. The chimeric Co-receptor according to claim 44, further wherein said at least one CD4 polypeptide region comprises the CD4palmitoylation motif region, and the CD4 LCK binding site region, optionally an entire CD4 cytoplasmic region; and further wherein said at least one CD4 polypeptide region comprises a CD4 transmembrane region.

46. The chimeric Co-receptor according to claim 45, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 27 (pTK-515), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or atleast 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 28 (pTK-516).

47. The chimeric Co-receptor according to claim 44, further wherein said at least one CD4polypeptide region comprises the CD4palmitoylation motif region, and the CD4 LCK binding site region, for example an entire CD4 cytoplasmic region; and further wherein said at least one CD8a polypeptide region comprises a CD8a transmembrane region.

48. The chimeric Co-receptor according to claim 47, wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 29 (pTK-517), or wherein the polypeptide is having an amino acid sequence with at least 85%, optionally with at least at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in SEQ ID NO: 30 (pTK-518).

49. An isolated nucleic acid comprising a nuclear acid sequence encoding for the chimeric CD8 Co-receptor according to any one of claims 1-48.

50. The isolated nucleic acid according to claim 49, wherein the nucleic acid sequence encoding for the chimeric CD8 Co-receptor is selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51 , SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 , SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 SEQ ID NO: 61 , SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO:66, SEQ ID NO: 71 , SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 89, and SEQ ID NO: 91.

51. A vector comprising the nucleic acid according to any one of claims 49 or 50.

52. The vector of claim 51 , wherein the vector is a viral vector or a non-viral vector.

53. The vector of claim 51 or claim 52, wherein the vector is a viral vector.

54. The vector of claim 53, wherein the viral vector is selected from adenoviruses, poxviruses, alphaviruses, arenaviruses, flaviruses, rhabdoviruses, retroviruses, lentiviruses, herpesviruses, paramyxoviruses, picornaviruses, and combinations thereof.

55. The vector of any one of claims 52-54, wherein the vector further comprises a nucleic acid encoding a chimeric antigen receptor (CAR).

56. The vector of any one of claims 52-55, wherein the vector further comprises a nucleic acid encoding a T-cell receptor comprising a TCR a chain and a TCR p chain.

57. The vector according to claim 56, wherein the T-cell receptor is a recombinant T- cell receptor.

58. An isolated T-cell, the T-cell being transformed, transduced or transfected with the nucleic acid according to any one of claim 49 or claim 50.

59. An isolated T-cell, the T-cell being transformed, transduced or transfected with the vector of any one of claims 39-45.

60. An isolated T-cell, the T-cell being transformed, transduced or transfected to express the chimeric CD8 Co-receptor of any one of the claims 1 - 48.

61. The T-cell of any one of claims 58 - 60, wherein the T-cell expresses the chimeric CD8 Co-receptor according to any one of claims 1 - 48.

62. A T-cell, wherein the T-cell expresses the chimeric CD8 Co-receptor of any one of the claims 1 - 48.

63. The T-cell of any one of claims 58-62, wherein the T-cell expresses a heterologous T-cell receptor.

64. The T-cell of any one of claims 58-63, wherein the cell is a ap T-cell, y8 T-cell , and / or a natural killer T-cell .

65. The T-cell of claim 64; wherein the p T-cell is a CD4 T-cell , or wherein the ap T-cell is a CD8 T-cell , or wherein the y8 T-cell is a Vy9V82+ T-cell.

66. A kit comprising means to prepare the T-cell according to any one of claims 58- 65.

67. A pharmaceutical composition comprising the T-cell of any one of claims 58-65.

68. The pharmaceutical composition of claim 67, wherein the composition further comprises an adjuvant, excipient, buffer, diluent, carrier, stabilizer or combination thereof.

69. A method for preparing a T-cell for immunotherapy, comprising isolating T-cell from a human subject, transducing, transforming or transfecting the T-cell with the nucleic acid of any one of claims 49-50, or with the vector of any one of claims 51-57, and expanding the transduced, transfected or transformed T-cell.

70. A method for treating a patient having a disease, comprising introducing in vivo the nucleic acid according to claim 45 or the vector according to claim 46 into a T-cell of the patient.

71. The method according to claim 70, wherein the nucleic acid is a DNA or a mRNA.

72. The method according to claim 70, wherein the vector is a non-replicating viral vector.

73. The method according to claim 70 or 71 , wherein the nucleic acid is mRNA, and wherein the mRNA is introduced into the T-cell of the patient using nanoparticles.

74. A pharmaceutical composition comprising a T-cell expressing the chimeric CD8 Co-receptor according to claim 1-48.

75. A method for treating a patient having cancer, comprising administering to the patient the composition of claims 67, 68, or 74.

76. The method according to claim 75, wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, pancreatic cancer, ovarian cancer, melanoma, breast cancer, liver cancer, kidney cancer, esophageal cancer, brain cancer, gastric cancer, Merkel cell carcinoma, leukemia, urinary bladder cancer, uterine cancer, colorectal cancer, gallbladder cancer, bile duct cancer, and prostate cancer.

Images